Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation.

Egger C, Muehlbacher M, Schatz M, Nickel M.

J Clin Psychopharmacol. 2007 Oct;27(5):475-8.

PMID:
17873679
2.

Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study.

Nickel MK, Nickel C, Muehlbacher M, Leiberich PK, Kaplan P, Lahmann C, Tritt K, Krawczyk J, Kettler C, Egger C, Rother WK, Loew TH.

J Clin Psychopharmacol. 2005 Jun;25(3):211-7.

PMID:
15876898
3.

Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.

Narula PK, Rehan HS, Unni KE, Gupta N.

Schizophr Res. 2010 May;118(1-3):218-23. doi: 10.1016/j.schres.2010.02.001. Epub 2010 Mar 7.

PMID:
20207521
4.

Topiramate's effectiveness on weight reduction in overweight/obese persons with schizophrenia: study protocol for a randomized controlled trial.

Chandradasa M, Champika L, de Silva S, Kuruppuarachchi KALA.

Trials. 2017 Sep 20;18(1):435. doi: 10.1186/s13063-017-2162-6.

5.
6.

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.

Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH.

Am J Clin Nutr. 2012 Feb;95(2):297-308. doi: 10.3945/ajcn.111.024927. Epub 2011 Dec 7.

7.

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.

Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M; OBES-002 Study Group.

Int J Obes Relat Metab Disord. 2004 Nov;28(11):1399-410.

PMID:
15486569
8.

Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.

Ellinger LK, Ipema HJ, Stachnik JM.

Ann Pharmacother. 2010 Apr;44(4):668-79. doi: 10.1345/aph.1M550. Epub 2010 Mar 16. Review.

PMID:
20233913
9.

Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder.

Vieta E, Sánchez-Moreno J, Goikolea JM, Colom F, Martínez-Arán A, Benabarre A, Corbella B, Torrent C, Comes M, Reinares M, Brugue E.

J Clin Psychopharmacol. 2004 Aug;24(4):374-8.

PMID:
15232327
10.

A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia.

Kim JH, Yim SJ, Nam JH.

Schizophr Res. 2006 Feb 15;82(1):115-7. Epub 2005 Dec 2. No abstract available.

PMID:
16326074
11.

Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F, Sun X, Fitchet M.

Int J Obes (Lond). 2007 Jan;31(1):138-46. Epub 2006 May 16.

PMID:
16703004
12.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
13.

Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate.

Lin YH, Liu CY, Hsiao MC.

Psychiatry Clin Neurosci. 2005 Oct;59(5):613-5.

14.

Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes.

Stenlöf K, Rössner S, Vercruysse F, Kumar A, Fitchet M, Sjöström L; OBDM-003 Study Group.

Diabetes Obes Metab. 2007 May;9(3):360-8.

PMID:
17391164
15.

Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial.

Afshar H, Roohafza H, Mousavi G, Golchin S, Toghianifar N, Sadeghi M, Talaei M.

J Psychopharmacol. 2009 Mar;23(2):157-62. doi: 10.1177/0269881108089816. Epub 2008 May 30.

PMID:
18515465
16.

Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study.

Nickel C, Lahmann C, Tritt K, Muehlbacher M, Kaplan P, Kettler C, Krawczyk J, Loew TH, Rother WK, Nickel MK.

J Affect Disord. 2005 Aug;87(2-3):243-52.

PMID:
15985295
17.

Topiramate in treatment of patients with chronic low back pain: a randomized, double-blind, placebo-controlled study.

Muehlbacher M, Nickel MK, Kettler C, Tritt K, Lahmann C, Leiberich PK, Nickel C, Krawczyk J, Mitterlehner FO, Rother WK, Loew TH, Kaplan P.

Clin J Pain. 2006 Jul-Aug;22(6):526-31.

PMID:
16788338
18.

Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up.

Nickel MK, Loew TH.

Eur Psychiatry. 2008 Mar;23(2):115-7. Epub 2007 Nov 19.

PMID:
18024088
19.

Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents.

Mahmood S, Booker I, Huang J, Coleman CI.

J Clin Psychopharmacol. 2013 Feb;33(1):90-4. doi: 10.1097/JCP.0b013e31827cb2b7. Review.

PMID:
23277264
20.

Comment: Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.

Hahn MK, Cohn T, Remington G.

Ann Pharmacother. 2010 Jul-Aug;44(7-8):1349-50; author reply 1350-1. doi: 10.1345/aph.1M550a. Epub 2010 Jun 29. No abstract available.

PMID:
20587740

Supplemental Content

Support Center